Title of article
HLA-B51 IN BEHÇET’S DISEASE
Author/Authors
Davatchi, F Department of Rheumatology - Rheumatology Research Center - Shariati Hospital - Tehran University of Medical Sciences - Tehran, Iran , Shahram, F. Department of Rheumatology - Rheumatology Research Center - Shariati Hospital - Tehran University of Medical Sciences - Tehran, Iran , Nadji, A. Department of Rheumatology - Rheumatology Research Center - Shariati Hospital - Tehran University of Medical Sciences - Tehran, Iran , Soroosh, S. Department of Rheumatology - Rheumatology Research Center - Shariati Hospital - Tehran University of Medical Sciences - Tehran, Iran , Jamshidi, A. R. Department of Rheumatology - Rheumatology Research Center - Shariati Hospital - Tehran University of Medical Sciences - Tehran, Iran , Chams, C. Department of Rheumatology - Rheumatology Research Center - Shariati Hospital - Tehran University of Medical Sciences - Tehran, Iran , Chams, H. Department of Rheumatology - Rheumatology Research Center - Shariati Hospital - Tehran University of Medical Sciences - Tehran, Iran , Akbarian, M Department of Rheumatology - Rheumatology Research Center - Shariati Hospital - Tehran University of Medical Sciences - Tehran, Iran , Gharibdoost, F. Department of Rheumatology - Rheumatology Research Center - Shariati Hospital - Tehran University of Medical Sciences - Tehran, Iran , Akhlaghi, M. Department of Rheumatology - Rheumatology Research Center - Shariati Hospital - Tehran University of Medical Sciences - Tehran, Iran , Sadeghi Abdollahi, B. Department of Rheumatology - Rheumatology Research Center - Shariati Hospital - Tehran University of Medical Sciences - Tehran, Iran , Ziaie, N Department of Rheumatology - Rheumatology Research Center - Shariati Hospital - Tehran University of Medical Sciences - Tehran, Iran
Pages
4
From page
507
To page
510
Abstract
There is some data in the literature on the association of HLA-B5 and some manifestations
of Behçet’s disease (BD), especially ocular lesions. We studied 433 patients to see if there was any
relationship between B51 and the manifestations of the disease. Clinical manifestations of BD were
compared in patients having HLA-B51 (155 patients) and those lacking HLA-B51 (278 patients). Oral
aphthosis, genital aphthosis, skin manifestations, joint manifestations, gastrointestinal manifestations,
phlebitis and neurological manifestations showed no significant difference in patients with and without
HLA-B51. Ophthalmologic manifestations were seen in 52% of patients having B51 and in 42% of
patients lacking it (χ2: 4.451, P = 0.035). Considering different lesions of ocular manifestations
separately, no significant difference was found regarding the presence or absence of B51. Pathergy
phenomenon was detected in 55% of B51 positive patients and in 45% of B51 negative patients (χ2:
4.111, P = 0.043). It seems that HLA-B51 may play a role in the pathogenesis of Behçet’s disease, but
cannot be used as predictive value for the occurrence of organ involvement, except for the eye.
Keywords
HLA-B51 , HLA-B5 , HLA typing , Behçet’s disease
Journal title
Astroparticle Physics
Serial Year
2008
Record number
2446314
Link To Document